AZD1979 is a potent and selective antagonist of the C-C chemokine receptor type 2 (CCR2). It is primarily used in oncology and immunology research to investigate its potential in blocking monocyte/macrophage recruitment to tumor sites and inflammatory areas. By inhibiting CCR2 signaling, it aims to reduce tumor growth, metastasis, and inflammation-associated pathologies. Researchers are exploring its efficacy in preclinical models to assess its ability to suppress cancer progression and immune cell infiltration. The compound is of interest for developing targeted therapies in cancers driven by chemokine-mediated inflammation, such as solid tumors. Studies focus on its pharmacokinetics, pharmacodynamics, and safety to evaluate potential for clinical translation. AZD1979 represents a promising tool in the search for novel anti-cancer and anti-inflammatory treatments.